Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs. A small ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met ...

Zenas BioPharma (NASDAQ:ZBIO) shares plunged about 50% after the company released results from its Phase 3 INDIGO study ...

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The study, Step-Up HS, will evaluate Rinvoq ...

Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high likelihood of success, CEO Thomas Schinecker has revealed. Pointing to a slump ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...